×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SABS – sab biotherapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SABS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
07:02 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
12/18
08:05 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Low
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
12/18
08:00 am
sabs
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
Low
Report
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
12/17
08:43 am
sabs
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D [Yahoo! Finance]
Medium
Report
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D [Yahoo! Finance]
12/17
08:00 am
sabs
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
Medium
Report
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
12/8
08:00 am
sabs
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
High
Report
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
11/22
02:11 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Wall Stree
Medium
Report
SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Wall Stree
11/17
08:06 am
sabs
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
High
Report
SAB Biotherapeutics (NASDAQ:SABS) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/18
04:55 pm
sabs
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: SKYLER JAY S
Low
Report
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: SKYLER JAY S
12/18
04:53 pm
sabs
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: Polvino William James
Low
Report
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: Polvino William James
12/18
04:50 pm
sabs
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: Lucera Erick
Low
Report
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: Lucera Erick
12/18
04:45 pm
sabs
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: Ellias Helen K.
Low
Report
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: Ellias Helen K.
12/18
04:43 pm
sabs
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: Giberson Scott
Low
Report
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: Giberson Scott
12/18
04:40 pm
sabs
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: Link David
Low
Report
Form 4 SAB Biotherapeutics, For: Dec 16 Filed by: Link David
12/12
04:45 pm
sabs
Form 4 SAB Biotherapeutics, For: Dec 11 Filed by: Kropotova Alexandra
Medium
Report
Form 4 SAB Biotherapeutics, For: Dec 11 Filed by: Kropotova Alexandra
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: